Target intelligence / Profile preview

Phosphatidylinositol glycan anchor biosynthesis class F pseudogene 3 (PIGFP3)

Target
PIGFP3
Molecular classification
Other, Pseudogene
01

Overview

Phosphatidylinositol glycan anchor biosynthesis class F pseudogene 3 (PIGFP3) is a processed or unprocessed pseudogene related to the phosphatidylinositol glycan anchor biosynthesis class F gene (PIGF). Pseudogenes like PIGFP3 typically resemble protein-coding genes but have accumulated mutations that prevent them from producing a functional protein. Although historically considered nonfunctional "genomic relics," some pseudogenes can impact biological processes at the DNA, RNA, or even peptide/protein level, often via gene regulation rather than direct activity as enzymes, receptors, or transporters[1][2][4]. Such regulatory effects include functioning as antisense RNAs, small interfering RNAs (siRNAs), or competing endogenous RNAs that modulate the expression of their parental genes or participate in complex regulatory networks. However, PIGFP3 is not an established drug or therapeutic target and no direct molecular, clinical, or biomarker roles are reported for it. In scientific and clinical contexts, the main interest in pseudogenes is as potential modulators of disease via indirect gene expression effects.

Other names
phosphatidylinositol glycan anchor biosynthesis, class F pseudogenePIGFP3
02

Biological functions

Regulation of parental gene expression via potential lncRNA activity or competing endogenous RNA (ceRNA) mechanismsPossible involvement in RNA-mediated gene regulatory networks
03

Disease associations

Pseudogenes have emerging associations with cancer as modifiers of gene expression, but no direct evidence for PIGFP3 specifically

Beyond the preview

Go deeper on Phosphatidylinositol glycan anchor biosynthesis class F pseudogene 3 (PIGFP3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phosphatidylinositol glycan anchor biosynthesis class F pseudogene 3 (PIGFP3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call